Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

2020 World Conference on Lung cancer

Thursday 28th - Sunday 31st January 2021

IASLC 2020 World Conference on Lung Cancer

Lung Cancer

KRAS inhibition comes of age for lung cancer?

A phase 2 study of sotorasib in advanced KRAS p.G12C mutated non-small cell lung cancer has delivered promising results including a disease control rate of 80.6%. Dr Bob Li, from the Memorial Sloan Kettering Cancer Centre in the US, presented the...

A phase 2 study of sotorasib in advanced KRAS p.G12C mutated non-small cell lung cancer has delivered promising results including...

Cancel